Skip to content

Instantly share code, notes, and snippets.

@xanderdunn

xanderdunn/tgfbeta_drugs.csv

Created July 23, 2019 17:52
Show Gist options
  • Star 0 You must be signed in to star a gist
  • Fork 0 You must be signed in to fork a gist
  • Save xanderdunn/7c4409c23d724a3f768fc5592f2c32b8 to your computer and use it in GitHub Desktop.
Save xanderdunn/7c4409c23d724a3f768fc5592f2c32b8 to your computer and use it in GitHub Desktop.
Download ZIP
Raw
tgfbeta_drugs.csv
Company Founded Product Type Furthest Research Started Fate Outcome Notes
Wyeth Pharmaceuticals (Pfizer) stamulumab (MYO-029) antibody Phase 2 Clinical Muscular Dystrophy 2005 dead didn't achieve significant muscle gain
Novartis & MorphoSys 1992 bimagrumab (BYM-338) antibody Phase 2b/3 Sporadic Inclusion Body Myositis 2013 dead didn't achieve significant muscle gain
Phase 2 Hip Fracture 2014 ongoing
Phase 2 Sarcopenia 2012 completed
Phase 2 Chronic Obstructive Pulmonary Disease 2012 completed
Phase 2 Cachexia 2011 completed
Phase 2 Diabetes 2016 ongoing
Scholar Rock 2012 SRK-015 antibody Expected to file IND Q2 2018 for spinal muscular atrophy ongoing
Atara (Amgen) 2012 PINTA-745 peptibody Phase 2 End Stage Renal Disease 2013 dead didn't achieve significant muscle gain
Acceleron & Shire 2004/1986 ACE-031 antibody Phase 2 Muscular Dystrophy 2010 dead toxicity
ACE-083 protein FSHD 2016 ongoing
Phase 2 Charcot-Marie-Tooth Disease 2017 ongoing
ACE-2494 protein Phase 1 Healthy Volunteers 2018 ongoing
Milo Biotechnology 2011 rAAV1.CMV.huFollistin344 gene Phase 1/2 Muscular Dystrophy 2012 ongoing
Pfizer 1849 domagrozumab (PF-06252616) anitbody Phase 2 Muscular Dystrophy 2016 dead didn't achieve significant muscle gain
Phase 1b/2 LGMD2I 2016 dead
Eli Lilly 1876 landogrozumab (LY2495655) antibody Phase 2 Advanced Cancer 2012 completed
Phase 2 Muscle Weakness 2012 completed
Phase 2 Muscle Atrophy 2011 dead didn't achieve significant muscle gain
Bristol-Myers Squibb & Roche 1887/1896 BMS-986089 protein Phase 2/3 Duchenne Muscular Dystrophy 2017 ongoing
Immusoft 2009 cell Expect to file IND Q4 2019 ongoing
AliveGen 2014 unknown Phase I unknown unknown
Paranta Bio 2009 PB01 protein (recombinant FST 288) Sam Coleman mentioned
Ossianix 2011 antibody Sam Coleman mentioned
Regeneron 1988 GARETOSMAB antibody (activin A) Phase 2 Fibrodysplasia Ossificans Progressiva
TREVOGRUMAB antibody (GDF8) Phase 1 Muscle-wasting diseases
Genentech & Roche 1976/1896 RG6206
AAVogen 2015
Sign up for free to join this conversation on GitHub. Already have an account? Sign in to comment